22 results
6-K
EX-99.1
CALT
Calliditas Therapeutics AB
25 Apr 24
Current report (foreign)
4:06pm
shall offer remuneration in accordance with market practice which enables the recruitment and retention of qualified executives. Remunerations within … for AGM 2024. Calliditas shall offer remuneration in accordance with market practice to enable the recruit-ment and retention of qualified executive
6-K
EX-99.1
CALT
Calliditas Therapeutics AB
28 Apr 23
Current report (foreign)
4:05pm
remuneration in accordance with market practice which enables the recruitment and retention of qualified executives. Remunerations within the Group shall … the effects of the hormone angio-tensin II, which has a constricting effect on blood vessels and stim-ulates salt and water retention in the body and thus
F-3
EX-1.2
a5dljoq2njk
28 Jun 22
Shelf registration (foreign)
4:49pm
6-K
EX-99.1
kki8u2 gmk9udct
29 Apr 22
Current report (foreign)
4:02pm
6-K
EX-10.1
14pj2l
23 Jul 21
Calliditas Therapeutics and STADA partner to register and commercialize specialty therapy for IgA Nephropathy in Europe
4:03pm
6-K
EX-10.1
qk0u jj6v
19 Jul 21
Calliditas secures $75 million term loan facility
7:20am
6-K
EX-10.2
89h445vrjywwn
19 Jul 21
Calliditas secures $75 million term loan facility
7:20am
20-F
oedvu
27 Apr 21
Annual report (foreign)
5:16pm
6-K
EX-99.1
2uyqx82q snq
27 Apr 21
Current report (foreign)
12:00am
F-1
EX-2.1
57w inb8dj68
26 Jan 21
Registration statement (foreign)
4:33pm
F-1
01ypbh2i75o 5dn2exaz
26 Jan 21
Registration statement (foreign)
4:33pm
DRS
jykdord72g27ye622z8
29 Dec 20
Draft registration statement
12:00am
424B4
eiptncj9esas5t0zh
8 Jun 20
Prospectus supplement with pricing info
9:18am
F-1/A
0gwwt bvdsugf878ned
1 Jun 20
Registration statement (foreign) (amended)
7:01am
F-1
cw689 4q5d8o
14 May 20
Registration statement (foreign)
8:56am
F-1
EX-10.1
z1w8o7k 8d509
14 May 20
Registration statement (foreign)
8:56am